Outcome Comparison of High-Risk Native American Patients Who Did or Did Not Receive Monoclonal Antibody Treatment for COVID-19-Reference-Cited by-同舟云学术

Outcome Comparison of High-Risk Native American Patients Who Did or Did Not Receive Monoclonal Antibody Treatment for COVID-19

Published:2021-09-21 Issue:9 Volume:4 Page:e2125866
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Close Ryan M.¹,Jones T. Shaifer¹,Jentoft Christopher¹,McAuley James B.¹

Affiliation:

1. Whiteriver Indian Hospital, Indian Health Service, Whiteriver, Arizona

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2784401/close_2021_ld_210190_1631627517.46983.pdf

Reference6 articles.

1. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial.;Gottlieb;JAMA,2021

2. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19.;Weinreich;N Engl J Med,2021

3. Infectious disease mortality among American Indians and Alaska Natives, 1999-2009.;Cheek;Am J Public Health,2014

4. COVID-19 mortality among American Indian and Alaska Native persons—14 states, January-June 2020.;Arrazola;MMWR Morb Mortal Wkly Rep,2020

5. US Food and Drug Administration. Fact sheet for health care providers: emergency use authorization (EUA) of bamlanivimab and etesevimab. November 9, 2020. Updated May 14, 2021. Accessed January 29, 2021. https://www.fda.gov/media/145802/download

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID at the Whiteriver Indian Hospital;Clinical Infectious Diseases;2023-10-04

2. Integrated COVID-19 Interventions in a Native American Community: Arizona, December 25, 2021–January 31, 2022;American Journal of Public Health;2023-10

3. Real-world effectiveness of casirivimab and imdevimab among patients diagnosed with COVID-19 in the ambulatory setting: a retrospective cohort study using a large claims database;BMJ Open;2022-12

4. Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19;Infectious Diseases and Therapy;2022-10-01

5. Effectiveness of Subcutaneous Casirivimab and Imdevimab Relative to no COVID-19 Antibody Treatment Among Patients Diagnosed With COVID-19 in the Ambulatory Setting;2022-06-22